ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BBI Brickell Biotech Inc

2.35
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Brickell Biotech Inc NASDAQ:BBI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.35 2.26 2.88 0 01:00:00

Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)

06/09/2022 9:44pm

Edgar (US Regulatory)



September 6, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
RE: Brickell Biotech, Inc.
Registration Statement on Form S-1 
File No. 333-267254
To Whom It May Concern:
Reference is made to the Registration Statement on Form S-1 (File No. 333-267254) filed by Brickell Biotech, Inc. (the “Company”) with the Securities and Exchange Commission on September 2, 2022 (the “Registration Statement”). Pursuant to Rule 473(a) of the Securities Act of 1933, as amended (the “Securities Act”), the following delaying amendment, prescribed by Rule 473(a) of the Securities Act, is hereby incorporated into the facing page of the Registration Statement:
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The Company requests that the Staff contact Jonathan R. Zimmerman at jon.zimmerman@faegredrinker.com or (612) 766-8419 with any questions or comments.
 
BRICKELL BIOTECH, INC.
/s/ Robert B. Brown
Robert B. Brown
Chief Executive Officer


1 Year Brickell Biotech Chart

1 Year Brickell Biotech Chart

1 Month Brickell Biotech Chart

1 Month Brickell Biotech Chart

Your Recent History

Delayed Upgrade Clock